Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis. The company is also developing EB612 as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. In addition, it is developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and the first oral GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. more
Time Frame | ENTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.94% | 0.31% | -1.26% |
1-Month Return | 8.76% | 0.6% | -4.16% |
3-Month Return | 32.58% | -9.44% | -0.46% |
6-Month Return | 26.2% | -5.15% | 3.58% |
1-Year Return | 114.55% | 0.33% | 22.47% |
3-Year Return | -16.61% | 4.53% | 25.13% |
5-Year Return | -15.11% | 35.98% | 77.7% |
10-Year Return | -62.42% | 100.72% | 190.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 236.00K | 365.00K | 571.00K | 134.00K | 14.00K | [{"date":"2019-12-31","value":41.33,"profit":true},{"date":"2020-12-31","value":63.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":23.47,"profit":true},{"date":"2023-12-31","value":2.45,"profit":true}] |
Cost of Revenue | 210.00K | 209.00K | 373.00K | 101.00K | 56.00K | [{"date":"2019-12-31","value":56.3,"profit":true},{"date":"2020-12-31","value":56.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":27.08,"profit":true},{"date":"2023-12-31","value":15.01,"profit":true}] |
Gross Profit | 26.00K | 156.00K | 198.00K | 33.00K | (56.00K) | [{"date":"2019-12-31","value":13.13,"profit":true},{"date":"2020-12-31","value":78.79,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":16.67,"profit":true},{"date":"2023-12-31","value":-28.28,"profit":false}] |
Gross Margin | 11.02% | 42.74% | 34.68% | 24.63% | (400.00%) | [{"date":"2019-12-31","value":25.78,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":81.13,"profit":true},{"date":"2022-12-31","value":57.62,"profit":true},{"date":"2023-12-31","value":-935.9,"profit":false}] |
Operating Expenses | 11.48M | 11.29M | 12.41M | 13.05M | 8.86M | [{"date":"2019-12-31","value":87.97,"profit":true},{"date":"2020-12-31","value":86.51,"profit":true},{"date":"2021-12-31","value":95.13,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":67.89,"profit":true}] |
Operating Income | (11.45M) | (11.13M) | (12.22M) | (13.02M) | (8.89M) | [{"date":"2019-12-31","value":-1145400000,"profit":false},{"date":"2020-12-31","value":-1113300000,"profit":false},{"date":"2021-12-31","value":-1221700000,"profit":false},{"date":"2022-12-31","value":-1301700000,"profit":false},{"date":"2023-12-31","value":-889100000,"profit":false}] |
Total Non-Operating Income/Expense | 575.00K | 1.10M | (58.00K) | 166.00K | 81.00K | [{"date":"2019-12-31","value":52.13,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-5.26,"profit":false},{"date":"2022-12-31","value":15.05,"profit":true},{"date":"2023-12-31","value":7.34,"profit":true}] |
Pre-Tax Income | (10.79M) | (9.96M) | (12.25M) | (12.93M) | (8.86M) | [{"date":"2019-12-31","value":-1079500000,"profit":false},{"date":"2020-12-31","value":-996300000,"profit":false},{"date":"2021-12-31","value":-1224600000,"profit":false},{"date":"2022-12-31","value":-1293400000,"profit":false},{"date":"2023-12-31","value":-886000000,"profit":false}] |
Income Taxes | 84.00K | 20.00K | (59.00K) | 137.00K | 29.00K | [{"date":"2019-12-31","value":61.31,"profit":true},{"date":"2020-12-31","value":14.6,"profit":true},{"date":"2021-12-31","value":-43.07,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":21.17,"profit":true}] |
Income After Taxes | (10.88M) | (9.98M) | (12.19M) | (13.07M) | (8.89M) | [{"date":"2019-12-31","value":-1087900000,"profit":false},{"date":"2020-12-31","value":-998300000,"profit":false},{"date":"2021-12-31","value":-1218700000,"profit":false},{"date":"2022-12-31","value":-1307100000,"profit":false},{"date":"2023-12-31","value":-888900000,"profit":false}] |
Income From Continuous Operations | (10.79M) | (9.98M) | (12.19M) | (13.07M) | (9.93M) | [{"date":"2019-12-31","value":-1079500000,"profit":false},{"date":"2020-12-31","value":-998300000,"profit":false},{"date":"2021-12-31","value":-1218700000,"profit":false},{"date":"2022-12-31","value":-1307100000,"profit":false},{"date":"2023-12-31","value":-992900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (10.88M) | (9.98M) | (12.19M) | (13.07M) | (8.89M) | [{"date":"2019-12-31","value":-1087900000,"profit":false},{"date":"2020-12-31","value":-998300000,"profit":false},{"date":"2021-12-31","value":-1218700000,"profit":false},{"date":"2022-12-31","value":-1307100000,"profit":false},{"date":"2023-12-31","value":-888900000,"profit":false}] |
EPS (Diluted) | (0.89) | (0.23) | (0.62) | (0.45) | (0.36) | [{"date":"2019-12-31","value":-89,"profit":false},{"date":"2020-12-31","value":-23,"profit":false},{"date":"2021-12-31","value":-62,"profit":false},{"date":"2022-12-31","value":-45,"profit":false},{"date":"2023-12-31","value":-36,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ENTX | |
---|---|
Cash Ratio | 6.22 |
Current Ratio | 6.61 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ENTX | |
---|---|
ROA (LTM) | -70.61% |
ROE (LTM) | -144.67% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ENTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.17 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.83 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ENTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 878.02 |
P/B | 13.70 |
Price/FCF | NM |
EV/R | 826.17 |
EV/Ebitda | NM |
Entera Bio Ltd (ENTX) share price today is $2.36
Yes, Indians can buy shares of Entera Bio Ltd (ENTX) on Vested. To buy Entera Bio Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ENTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Entera Bio Ltd (ENTX) via the Vested app. You can start investing in Entera Bio Ltd (ENTX) with a minimum investment of $1.
You can invest in shares of Entera Bio Ltd (ENTX) via Vested in three simple steps:
The 52-week high price of Entera Bio Ltd (ENTX) is $3.35. The 52-week low price of Entera Bio Ltd (ENTX) is $0.68.
The price-to-earnings (P/E) ratio of Entera Bio Ltd (ENTX) is
The price-to-book (P/B) ratio of Entera Bio Ltd (ENTX) is 13.70
The dividend yield of Entera Bio Ltd (ENTX) is 0.00%
The market capitalization of Entera Bio Ltd (ENTX) is $86.92M
The stock symbol (or ticker) of Entera Bio Ltd is ENTX